PTJ
RVMD icon

Paul Tudor Jones’s Revolution Medicines RVMD Stock Holding History

Paul Tudor Jones’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Buy
+13,700
New +$2M ﹤0.01% 1768

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Paul Tudor Jones's RVMD Position: Q2 2026 in Review

Paul Tudor Jones reduced its Revolution Medicines (RVMD) stake by 82% in Q2 2026, selling an estimated $10.5M and leaving 16,000 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Paul Tudor Jones first reported a position in RVMD in Q2 2021 and has held it in 11 quarters since. The position peaked at $8.54M in Q1 2026. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Paul Tudor Jones held 16,000 shares of Revolution Medicines worth $3M as of Q2 2026.
  • Paul Tudor Jones sold 71,852 Revolution Medicines shares in Q2 2026, an estimated $10.5M.
  • Revolution Medicines made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1659 holding.
  • Paul Tudor Jones first reported a position in Revolution Medicines in Q2 2021 and has held it in 11 quarters since.
  • Paul Tudor Jones's Revolution Medicines position peaked at $8.54M in Q1 2026.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.